LONG BEACH, Calif., May 16, 2024 /PRNewswire/ — A new study to shed light on the long-term nephroprotective potential of sparsentan compared to maximally titrated irbesartan (MT-IRB) in patients with IgA nephropathy (IgAN) is set to be presented as a late-breaking presentation at the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
